Effect of Vitamin B12, Folate, and Entacapone in Levodopa-induced hyperhomocysteinemia

Not Applicable

Recruiting

• Conditions: Parkinson' s disease; s disease, Levodopa, Hyperhomocysteinemia, Entacapone, Vitamin B12, Folate

• Registration Number: TCTR20181221001
• Lead Sponsor: Research and Development Center, Prapokklao Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-21
• Study Completion: 2020-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

The PD patients who are being treated with levodopa at least 300 mg/day for at least 1 year.

Exclusion Criteria

1. Patients who are being treated with entacapone
2. Patients who are taking vitamin B12 or folate supplement.
3. Presence of the conditions influence homocysteine level are end stage renal disease, liver cirrhosis, smoking, malignancy, dementia, diabetes mellitus, hypothyroid, take thaizide diuretic, azathioprine, phenytoin, metrotrexate

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum homocysteine level at weeks 6 and 12 after treatment Blood testing

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A